Abstract

Objectives

Obesity is a global health problem and is associated with a chronic low-grade inflammatory state. Surgical obesity treatment is being increasingly common due to its efficacy. From this, we evaluate the metabolic state improvement and inflammation remission in patients with obesity undergoing bariatric surgery. Methods: The clinical data and serum levels of leptin and adiponectin were assessed in patients with obesity before and one, three and six months after bariatric surgery. Also, serum amyloid A (SAA), monocyte chemoattractant protein-1 (MCP-1) levels were measured during the follow-up surgery and compared with a lean group of individuals. Results: Weight loss decreased body mass index (BMI), comorbidities percentage, drugs use and leptin levels. Adiponectin levels increased after surgery. SAA and MCP-1 showed no difference after surgery, but a trend decrease for MCP-1 and a significant decrease was observed when the patients with obesity were compared to the lean participants. Conclusion: Bariatric surgery alters metabolic status improving obesity-related comorbidities and the adiposity biomarkers leptin and adiponectin, but not inflammatory cytokines SAA and MCP-1.

中文翻译：

---

经过六个月的随访，减肥手术改善了临床结果和肥胖生物标志物，但没有改善炎性细胞因子 SAA 和 MCP-1

摘要

目标

肥胖是一个全球性的健康问题，与慢性低度炎症状态有关。由于其疗效，手术肥胖症治疗越来越普遍。由此，我们评估了接受减肥手术的肥胖患者的代谢状态改善和炎症缓解。方法：评估肥胖患者在减肥手术前和术后1、3、6个月的临床资料和血清瘦素和脂联素水平。此外，在后续手术期间测量了血清淀粉样蛋白 A (SAA)、单核细胞趋化蛋白-1 (MCP-1) 水平，并与瘦个体进行了比较。结果：体重减轻会降低体重指数（BMI）、合并症百分比、药物使用和瘦素水平。手术后脂联素水平升高。手术后 SAA 和 MCP-1 没有差异，但 MCP-1 呈下降趋势，当肥胖患者与瘦参与者进行比较时观察到显着下降。结论：减肥手术改变代谢状态，改善肥胖相关合并症和肥胖生物标志物瘦素和脂联素，但不改变炎性细胞因子 SAA 和 MCP-1。